The Latest Analyst Ratings For Ultragenyx Pharmaceutical

In the latest quarter, 4 analysts provided ratings for Ultragenyx Pharmaceutical RARE, showcasing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $92.0, a high estimate of $114.00, and a low estimate of $68.00. Witnessing a positive shift, the current average has risen by 61.4% from the previous average price target of $57.00.

Decoding Analyst Ratings: A Detailed Look

In examining recent analyst actions, we gain insights into how financial experts perceive Ultragenyx Pharmaceutical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Ultragenyx Pharmaceutical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ultragenyx Pharmaceutical's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Ultragenyx Pharmaceutical analyst ratings.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical's Economic Impact: An Analysis

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Ultragenyx Pharmaceutical's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 8.1%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Ultragenyx Pharmaceutical's net margin excels beyond industry benchmarks, reaching -162.82%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -198.64%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -12.52%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio is below the industry average at 1.47, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Basics of Analyst Ratings

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.